Therapeutic Potential of HSP90 Inhibition for Neurofibromatosis Type 2

201343 citationsJournal Articlebronze Open Access

Authors

Karo Tanaka · Nexgenix Pharmaceuticals (United States)

Ascia Eskin · Nexgenix Pharmaceuticals (United States)

Fabrice Chareyre · Covance (United States)

Walter J. Jessen · Centre National de la Recherche Scientifique

Jan Manent · Université Paris Cité

Michiko Niwa‐Kawakita · Inserm

Ruihong Chen

Abstract

HSP90 inhibition showing significant antitumor activity against NF2-related tumor cells in vitro and in vivo represents a promising option for novel NF2 therapies.

Topics & Keywords

Neurofibromatosis and Schwannoma Cases Heat shock proteins research Neuroblastoma Research and Treatments

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Clinical Cancer Research

Volume 19, Issue 14, pp. 3856-3870

DOI: 10.1158/1078-0432.ccr-12-3167

Field-Weighted Citation Impact: 2.25